persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВАpersmed-3Research ArticleКОЛОНКА ГЛАВНОГО РЕДАКТОРАEDITORS CORNERПерсонализированная медицина. История, современное состояние проблемы и перспективы внедренияPersonalized Medicine. History, current state and future directionsШляхтоЕ. В.ShlyakhtoE. V.

Шляхто Евгений Владимирович, д.м.н., профессор, академик РАН, генеральный директор

Санкт-Петербург

Shlyakhto Evgeny V., MD, PhD, Dr. Sc., Professor, Academician of the Russian Academy of Science, Director; Director

Saint Petersburg

КонрадиА. О.KonradiA. O.

Конради Александра Олеговна, д.м.н., профессор, чл.-корр. РАН, заместитель генерального директора, заведующий кафедрой организации управления и экономики здравоохранения Института медицинского образования Центра Алмазова

ул. Аккуратова, д. 2, Санкт-Петербург, Россия, 197341

Konradi Alexandra O., MD, Dr. Sc., Professor, Corresponding Member RAS, Deputy General Director for Research, Head of the Research Department of Arterial Hypertension, Head of the Department of Management Organization and Health Economics, Institute of Medical Education

Akkuratova str. 2, Saint Petersburg, Russia, 197341

konradi_ao@almazovcentre.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Научный центр мирового уровня «Центр персонализированной медицины»РоссияAlmazov National Medical Research Centre; World-Class Research Centre for Personalized MedicineRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian Federation20212812202111620Copyright © Шляхто Е.В., Конради А.О., 20212021Шляхто Е.В., Конради А.О.Shlyakhto E.V., Konradi A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/3

В обзоре приводится история формирования направления персонализированной медицины, а также связанных с ней терминов и определений, оценка состояния проблемы на современном этапе и перспективы будущего. Приведен краткий анализ основных направлений персонализированной медицины и областей применения, преимущества подхода и барьеры на пути практического внедрения.

The review assesses history of personalized approach in medicine, terminology and definitions and current situation in personalized medicine in the world. Major fields of implementation, classification, advantages and practical barriers are also discussed as well as future perspectives.

персонализированная медицинапрецизионная медицинафармакогенетикаомиксные технологииpersonalized medicineprecision medicinepragmacogeneticsOMICs-technologiesReferencesSchwab K. The fourth industrial revolution. World Economic Forum. New York, NY: Crown Publishing Group, 2017.Schwab K. The fourth industrial revolution. World Economic Forum. New York, NY: Crown Publishing Group, 2017.Personalized medicines fact sheet. Genes to personalized medicines. Progress from the National Institute of General Medical Sciences. National Institute of Health. https://www.nih.gov/about-nih/what-wedo/nih-turning-discovery-into-health/personalizedmedicine (29 August 2021).Personalized medicines fact sheet. Genes to personalized medicines. Progress from the National Institute of General Medical Sciences. National Institute of Health. https://www.nih.gov/about-nih/what-wedo/nih-turning-discovery-into-health/personalizedmedicine (29 August 2021).Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genomics. 2015;8: 33. DOI: 10.1186/s12920-015-0108-y.Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med Genomics. 2015;8: 33. DOI: 10.1186/s12920-015-0108-y.Strategy of scientific and technological development of the Russian Federation (approved by the Decree of the President of the Russian Federation of December 1, 2016 No. 642). In Russian [Стратегия научно-технологического развития Российской Федерации (утверждена Указом Президента Российской Федерации от 1 декабря 2016 г. № 642)].Strategy of scientific and technological development of the Russian Federation (approved by the Decree of the President of the Russian Federation of December 1, 2016 No. 642). In Russian [Стратегия науч- но-технологического развития Российской Федерации (утверждена Указом Президента Российской Федерации от 1 декабря 2016 г. № 642)].National Research Council (US) Committee on a framework for developing a new taxonomy of disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington (DC): National Academies Press (US); 2011. PMID: 22536618.National Research Council (US) Committee on a framework for developing a new taxonomy of disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington (DC): National Academies Press (US); 2011. PMID: 22536618.Kirchhof P, Sipido KR, Cowie MR, et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J. 2014;35(46):3250–3257. DOI: 10.1093/eurheartj/ehu312.Kirchhof P, Sipido KR, Cowie MR, et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J. 2014;35(46):3250–3257. DOI: 10.1093/eurheartj/ehu312.Senn S. Mastering variation: variance components and personalised medicine. Stat Med. 2016;35(7):966–977. DOI: 10.1002/sim.6739.Senn S. Mastering variation: variance components and personalised medicine. Stat Med. 2016;35(7):966–977. DOI: 10.1002/sim.6739.Pan S, Knowles JW. Exploring predisposition and treatment response — the promise of genomics. Prog Cardiovasc Dis. 2012;55(1):56–63. DOI: 10.1016/j.pcad.2012.04.006.Pan S, Knowles JW. Exploring predisposition and treatment response — the promise of genomics. Prog Cardiovasc Dis. 2012;55(1):56–63. DOI: 10.1016/j.pcad.2012.04.006.Hwang J, Christensen CM. Disruptive innovation in health care delivery: a framework for business-model innovation. Health Aff (Millwood). 2008;27(5):1329–1335. DOI: 10.1377/hlthaff.27.5.1329.Hwang J, Christensen CM. Disruptive innovation in health care delivery: a framework for business-model innovation. Health Aff (Millwood). 2008;27(5):1329–1335. DOI: 10.1377/hlthaff.27.5.1329.Joyner MJ, Prendergast FG. Chasing Mendel: five questions for personalized medicine. J Physiol. 2014;592(Pt 11):2381–2388. DOI: 10.1113/jphysiol.2014.272336.Joyner MJ, Prendergast FG. Chasing Mendel: five questions for personalized medicine. J Physiol. 2014;592(Pt 11):2381–2388. DOI: 10.1113/jphysiol.2014.272336.Mayo clinic staff. Pharmacogenomics: when medicine gets personal. Mayo Foundation for Medical Education and Research (MFMER). July 16, 2010.Mayo clinic staff. Pharmacogenomics: when medicine gets personal. Mayo Foundation for Medical Education and Research (MFMER). July 16, 2010. 12. Jain KK. Personalized medicine. Waltham: Decision Resources Inc; 1998.Jain KK. Personalized medicine. Waltham: Decision Resources Inc; 1998.Garrod AE. The inborn factors in disease. London: Oxford University Press; 1931.Garrod AE. The inborn factors in disease. London: Oxford University Press; 1931.Kalow W. Familial incidence of low pseudocholinesterase level. Lancet. 1956;268(6942):576–577.Kalow W. Familial incidence of low pseudocholinesterase level. Lancet. 1956;268(6942):576–577.Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc. 1957;165(7):835–837. DOI: 10.1001/jama.1957.729802500100.Motulsky AG. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc. 1957;165(7):835–837. DOI: 10.1001/jama.1957.729802500100.Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: Saunders; 1962.Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: Saunders; 1962.Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symp Quant Biol. 1986;51 Pt 1:263–273. DOI: 10.1101/sqb.1986.051.01.032.Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symp Quant Biol. 1986;51 Pt 1:263–273. DOI: 10.1101/sqb.1986.051.01.032.O’Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era. Circ Cardiovasc Genet. 2008;1(1):51–57. DOI: 10.1161/CIRCGENETICS.108.813337.O’Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era. Circ Cardiovasc Genet. 2008;1(1):51–57. DOI: 10.1161/CIRCGENETICS.108.813337.Caulfield BM, Donnelly SC. What is Connected Health and why will it change your practice? QJM. 2013;106(8):703–707. DOI: 10.1093/qjmed/hct114.Caulfield BM, Donnelly SC. What is Connected Health and why will it change your practice? QJM. 2013;106(8):703–707. DOI: 10.1093/qjmed/hct114.Jain KK. Personalized medicine. Springer New York Heidelberg Dordrecht London. Springer Science+Business Media New York; 2015.Jain KK. Personalized medicine. Springer New York Heidelberg Dordrecht London. Springer Science+Business Media New York; 2015.Offit K. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130(1):3–14. DOI: 10.1007/s00439-011-1028-3.Offit K. Personalized medicine: new genomics, old lessons. Hum Genet. 2011;130(1):3–14. DOI: 10.1007/s00439-011-1028-3.Offit K. Genomic profiles for disease risk: predictive or premature? JAMA. 2008;299(11):1353–1355. DOI: 10.1001/jama.299.11.1353.Offit K. Genomic profiles for disease risk: predictive or premature? JAMA. 2008;299(11):1353–1355. DOI: 10.1001/jama.299.11.1353.Sherkow JS, Greely HT. The future of gene patents and the implications for medicine. JAMA Intern Med. 2013;173(17):1569–1570. DOI: 10.1001/jamainternmed.2013.10153.Sherkow JS, Greely HT. The future of gene patents and the implications for medicine. JAMA Intern Med. 2013;173(17):1569–1570. DOI: 10.1001/jamainternmed.2013.10153.Sherkow JS, Greely HT. The future of gene patents and the implications for medicine. JAMA Intern Med. 2013;173(17):1569–1570. DOI: 10.1001/jamainternmed.2013.10153.

The authors declare that there are no conflicts of interest present.